METHODS

Design:
Randomised controlled trial. Allocation: Unclear. Blinding: Double blinded. Follow-up period: 12 weeks (treatment period only).
MAIN RESULTS
There was no signifi cant difference between the citalopram and placebo groups in responders based on the CGI-I at 12 weeks (32.9% with citalopram vs 34.2% with placebo; relative risk 0.96; 95% CI 0.61 to 1.51). Both groups improved over time on the CGI-I but there was no difference between them (p=0.94). There was also no difference on the combined response criteria (CGI-I and CYBOCS-PDD; 20.6% with citalopram vs 13.2% with placebo; p=0.28). Compulsive and repetitive behaviours, as assessed by the CYBOCS-PDD and the six subscales of the RBS-R, also showed no differences between the groups. There was a small but statistically signifi cant difference between the citalopram and placebo groups for the change between baseline and 12 weeks in the irritability component of the ABC-CV but not in other components (mean difference irritability: −2.27, 95% CI −4.3 to −0.2; p=0.03). Adherence to treatment was high in both groups (96.1% for citalopram vs 98.6% for placebo; p=0.03). More adverse events occurred in the citalopram group than in the placebo group (absolute risk for at least one treatment related event: 97.3% with citalopram vs 86.8% with placebo; p=0.03). More participants receiving citalopram withdrew because of an adverse event (12.3% with citalopram vs 9.2% with placebo; signifi cance not reported).
CONCLUSIONS
Citalopram is not an effective treatment for children with autistic spectrum disorders with moderate or severe repetitive behaviour. More placebo controlled trials of medications used in these children are needed to assess whether the risks outweigh the benefi ts. Psychotropic medications, including selective serotonin reuptake inhibitors (SSRIs), are commonly prescribed for children and adolescents with autism spectrum disorders (ASDs) to target associated maladaptive behaviours, comorbid psychiatric conditions or even core symptoms of the disorder. 1 Previous small, double blind, placebo controlled randomised clinical trials of fl uvoxamine in adults (n=30) and fl uoxetine in children (n=39) have suggested that these SSRIs are superior to placebo for reducing repetitive behaviours associated with autism. 1 However, the majority of the published evidence supporting the use of SSRIs is from open label trials that are subject to publication bias, placebo effects and other shortcomings of uncontrolled trials. 1 In addition, although the details have not yet been published, Autism Speaks announced in 2009 that an industry sponsored controlled trial (n=158) demonstrated that fl uoxetine was not superior to placebo for reducing repetitive behaviours in children and adolescents with autistic disorder. 2 In this well designed, large, double blind, placebo controlled randomised clinical trial, King and colleagues found that citalopram was not superior to placebo for reduction of repetitive behaviour in children and adolescents with ASDs but was associated with signifi cantly more adverse behavioural effects and medical symptoms. The high placebo response rate of 34%, which has also been found in some other studies involving this population, 3 illustrates the importance of double blind, placebo controlled trials. Although the reduction in irritability associated with citalopram relative to placebo (p=0.03) was not clinically meaningful, the children who participated in this study were much less irritable at baseline than those who participated in previous risperidone trials, so the possibility that citalopram is effective for irritability in this population cannot be excluded.
ABSTRACTED FROM
Currently, the weight of evidence clearly does not support the use of SSRIs for the treatment of repetitive behaviours in children with ASDs. However, further investigation is necessary to determine whether SSRIs are effective for other target symptoms such as irritability or anxiety in this population.
